Progressive multiple sclerosis (PMS) lacks blood-based biomarkers of the neurodegenerative processes driving disability. We measured synaptopodin, a postsynaptic protein, in neuronal-enriched extracellular vesicles (NEVs) across two independent cohorts: the SPRINT-MS trial (n=184) and a real-world validation cohort (n=268). A one SD increase in baseline synaptopodin was associated with ~32% lower risk of confirmed disability progression in PMS (p=0.011), with the strongest effect in secondary PMS (SPMS) (~57% lower odds, p=0.019).
A Blood-Based Synaptic Biomarker in Neuronally-Enriched Extracellular Vesicles Predicts Disability Progression in Progressive Multiple Sclerosis
calendar_today
October 9, 2026
person
Jank, L., Kumar, M. K. S., Joshi, D., Minney, V., Eskinder, R., Thapa, R., Heller, J. G., Filippatou, A. G., Siavoshi, F., Smith, M. D., Harp, C., Abioye, I., Sotirchos, E. S., Dewey, B. E., Saidha, S., Fitzgerald, K. C., Calabresi, P. A., Mowry, E. M., Bhargava, P.
domain
medrxiv